Drugmaker Cipla on Wednesday announced the launch of Yurpeak (tirzepatide), a once-weekly injectable treatment for obesity and type-2 diabetes mellitus, two of India’s fastest-growing health challenges. The announcement was made through a regulatory filing.
Cipla said it has secured the rights to distribute and promote Yurpeak, which becomes the second tirzepatide brand from Eli Lilly in India, following DCGI’s approval for the molecule.
Tirzepatide is the first and only dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is approved as an adjunct to diet and exercise for managing type-2 diabetes and for chronic weight management in adults.
Yurpeak will be prescription-only, available in the KwikPen device across six dose strengths:
2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
Cipla on expanding access to advanced diabetes and obesity therapies
Commenting on the launch, Achin Gupta, Global Chief Operating Officer at Cipla, said the introduction of Yurpeak represents a “transformative moment” in tackling chronic diseases such as obesity and type-2 diabetes.
Gupta added that Cipla is entering this therapeutic area with the same scientific rigor that has shaped its leadership in chronic disease management and respiratory care.
He emphasized that partnerships like Cipla’s collaboration with Eli Lilly help “accelerate access to globally benchmarked, future-ready therapies” across India.
Pricing and supply model
Eli Lilly will manufacture and supply Yurpeak to Cipla, and the price will remain identical to Lilly’s Mounjaro, the company confirmed.
Cipla said the launch will significantly expand access to tirzepatide in India, enabling more patients to benefit from an innovative and globally recognized therapy.